EE05244B1 - Kinasoliinderivaadid, neid hendeid sisaldavad ravimid, nende kasutamine ja meetod nende valmistamiseks - Google Patents

Kinasoliinderivaadid, neid hendeid sisaldavad ravimid, nende kasutamine ja meetod nende valmistamiseks

Info

Publication number
EE05244B1
EE05244B1 EEP200300300A EEP200300300A EE05244B1 EE 05244 B1 EE05244 B1 EE 05244B1 EE P200300300 A EEP200300300 A EE P200300300A EE P200300300 A EEP200300300 A EE P200300300A EE 05244 B1 EE05244 B1 EE 05244B1
Authority
EE
Estonia
Prior art keywords
compounds
preparation
quinazoline derivatives
drugs containing
drugs
Prior art date
Application number
EEP200300300A
Other languages
English (en)
Estonian (et)
Inventor
Himmelsbach Frank
Langkopf Elke
Blech Stefan
Jung Birgit
Baum Anke
Solca Flavio
Original Assignee
Boehringer Ingelheim Pharma Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7667887&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE05244(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma Gmbh & Co. Kg filed Critical Boehringer Ingelheim Pharma Gmbh & Co. Kg
Publication of EE200300300A publication Critical patent/EE200300300A/xx
Publication of EE05244B1 publication Critical patent/EE05244B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
EEP200300300A 2000-12-20 2001-12-12 Kinasoliinderivaadid, neid hendeid sisaldavad ravimid, nende kasutamine ja meetod nende valmistamiseks EE05244B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10063435A DE10063435A1 (de) 2000-12-20 2000-12-20 Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
PCT/EP2001/014569 WO2002050043A1 (de) 2000-12-20 2001-12-12 Chinazolinderivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung

Publications (2)

Publication Number Publication Date
EE200300300A EE200300300A (et) 2003-10-15
EE05244B1 true EE05244B1 (et) 2009-12-15

Family

ID=7667887

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300300A EE05244B1 (et) 2000-12-20 2001-12-12 Kinasoliinderivaadid, neid hendeid sisaldavad ravimid, nende kasutamine ja meetod nende valmistamiseks

Country Status (39)

Country Link
EP (2) EP1345910B9 (en, 2012)
JP (1) JP3827641B2 (en, 2012)
KR (1) KR100852102B1 (en, 2012)
CN (1) CN1277822C (en, 2012)
AR (1) AR040524A1 (en, 2012)
AT (1) ATE430136T1 (en, 2012)
AU (2) AU1917402A (en, 2012)
BE (1) BE2014C009I2 (en, 2012)
BG (1) BG66139B1 (en, 2012)
BR (1) BRPI0116266B8 (en, 2012)
CA (1) CA2432428C (en, 2012)
CY (2) CY1109290T1 (en, 2012)
CZ (1) CZ302721B6 (en, 2012)
DE (2) DE10063435A1 (en, 2012)
DK (1) DK1345910T3 (en, 2012)
EA (1) EA006317B1 (en, 2012)
EE (1) EE05244B1 (en, 2012)
ES (1) ES2326617T3 (en, 2012)
FR (1) FR14C0009I2 (en, 2012)
HR (1) HRP20030504B1 (en, 2012)
HU (2) HU228874B1 (en, 2012)
IL (2) IL156277A0 (en, 2012)
LT (1) LTC1345910I2 (en, 2012)
LU (1) LU92370I2 (en, 2012)
ME (1) ME02777B (en, 2012)
MX (1) MXPA03005559A (en, 2012)
MY (1) MY136086A (en, 2012)
NO (3) NO325672B1 (en, 2012)
NZ (1) NZ526918A (en, 2012)
PL (1) PL214798B1 (en, 2012)
PT (1) PT1345910E (en, 2012)
RS (1) RS50860B (en, 2012)
SI (1) SI1345910T1 (en, 2012)
SK (1) SK287573B6 (en, 2012)
TW (1) TWI295992B (en, 2012)
UA (1) UA74614C2 (en, 2012)
UY (1) UY27078A1 (en, 2012)
WO (1) WO2002050043A1 (en, 2012)
ZA (1) ZA200304141B (en, 2012)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1731511T3 (en) 1999-06-21 2015-10-26 Boehringer Ingelheim Pharma Bicyclic heterocyclic structures, pharmaceutical compositions containing these compounds, their use and process for their preparation
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
DE10204462A1 (de) * 2002-02-05 2003-08-07 Boehringer Ingelheim Pharma Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US20040044014A1 (en) 2002-04-19 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
DE10221018A1 (de) 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
PE20040945A1 (es) * 2003-02-05 2004-12-14 Warner Lambert Co Preparacion de quinazolinas substituidas
DE10307165A1 (de) * 2003-02-20 2004-09-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung
US7223749B2 (en) 2003-02-20 2007-05-29 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
DE10334226A1 (de) * 2003-07-28 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
GB0317665D0 (en) 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
WO2005026150A1 (en) 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
US7456189B2 (en) 2003-09-30 2008-11-25 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
DE10349113A1 (de) 2003-10-17 2005-05-12 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Aminocrotonylverbindungen
SI1746999T1 (sl) * 2004-05-06 2012-01-31 Warner Lambert Co 4-fenilamino-kinazolin-6-il-amidi
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
WO2006081741A1 (fr) * 2005-02-05 2006-08-10 Piaoyang Sun Dérivés de quinazoline ou leurs sels de qualité pharmaceutique, synthèse et applications médicales desdites substances
KR100832594B1 (ko) * 2005-11-08 2008-05-27 한미약품 주식회사 다중저해제로서의 퀴나졸린 유도체 및 이의 제조방법
ES2412879T3 (es) * 2005-11-11 2013-07-12 Boehringer Ingelheim International Gmbh Tratamiento combinado del cáncer que comprende inhibidores de EGFR/HER2
EP1948179A1 (en) 2005-11-11 2008-07-30 Boehringer Ingelheim International GmbH Quinazoline derivatives for the treatment of cancer diseases
CA2639936C (en) * 2006-01-26 2014-06-17 Boehringer Ingelheim International Gmbh Process for preparing aminocrotonylamino-substituted quinazoline derivatives
ES2385613T3 (es) * 2006-09-18 2012-07-27 Boehringer Ingelheim International Gmbh Método para tratar cánceres que portan mutaciones de EGFR
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
WO2008095847A1 (de) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
EA019709B1 (ru) 2008-02-07 2014-05-30 Бёрингер Ингельхайм Интернациональ Гмбх Спирогетероциклы и их применение в качестве лекарственных средств
NZ589883A (en) 2008-05-13 2012-06-29 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy} quinazoline
UY31867A (es) 2008-06-06 2010-01-29 Boehringer Ingelheim Int Nuevas formulaciones farmacéuticas sólidas que comprenden bibw 2992
US8426430B2 (en) 2008-06-30 2013-04-23 Hutchison Medipharma Enterprises Limited Quinazoline derivatives
US8648191B2 (en) 2008-08-08 2014-02-11 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
JP5781934B2 (ja) * 2008-11-10 2015-09-24 ナショナル ヘルス リサーチ インスティテューツ チロシンキナーゼ阻害剤としての融合２環および３環ピリミジン化合物
EP2387401A1 (en) 2009-01-14 2011-11-23 Boehringer Ingelheim International GmbH Method for treating colorectal cancer
US20120136004A1 (en) * 2009-05-14 2012-05-31 Boehringer Ingelheim International Gmbh New combination therapy in treatment of cancer and fibrotic diseases
US20120142703A1 (en) 2009-05-14 2012-06-07 Boehringer Ingelheim International Gmbh New combination therapy in treatment of oncological and fibrotic diseases
JP5963672B2 (ja) 2009-07-06 2016-08-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｉｂｗ２９９２、その塩及びこの活性成分を含む固体医薬製剤の乾燥方法
JP2013512882A (ja) 2009-12-07 2013-04-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング トリプルネガティブ乳癌の治療に使用するｂｉｂｗ２９９２
CN105037333A (zh) * 2009-12-21 2015-11-11 张强 新的喹唑啉衍生物
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
HUE038049T2 (hu) 2010-08-26 2018-09-28 Boehringer Ingelheim Int Eljárások EGFR-inhibitor adagolására
CN103476770B (zh) * 2010-11-25 2017-02-15 拉蒂欧制药有限责任公司 阿法替尼盐和多晶型物
CA2828713C (en) 2011-03-04 2022-08-16 Newgen Therapeutics, Inc. Alkyne substituted quinazoline compounds and methods of use
US8828391B2 (en) 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer
CN102918029B (zh) * 2011-05-17 2015-06-17 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
CN102838590B (zh) * 2011-06-21 2014-07-09 苏州迈泰生物技术有限公司 氨基喹唑啉衍生物及其在制备抗恶性肿瘤药物中的用途
WO2013052157A1 (en) 2011-10-06 2013-04-11 Ratiopharm Gmbh Crystalline forms of afatinib di-maleate
CN103073539B (zh) * 2011-10-26 2016-05-11 齐鲁制药有限公司 4-(取代苯氨基)喹唑啉衍生物及其制备方法、药物组合物和用途
SI2805940T1 (sl) 2012-01-17 2017-04-26 Astellas Pharma Inc Pirazinkarboksamidna spojina
CN103772380A (zh) * 2012-10-23 2014-05-07 杨子娇 一类治疗房角狭窄的化合物及其用途
EP2951171A1 (en) 2013-02-01 2015-12-09 Boehringer Ingelheim International GmbH Radiolabeled quinazoline derivatives
ES2702174T3 (es) 2013-04-05 2019-02-27 Boehringer Ingelheim Int Usos terapéuticos de empagliflozina
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HK1213818A1 (zh) 2013-04-05 2016-07-15 勃林格殷格翰国际有限公司 依帕列净的治疗用途
LT2986304T (lt) 2013-04-18 2022-03-10 Boehringer Ingelheim International Gmbh Farmacinė kompozicija, gydymo būdai ir jų panaudojimas
CN103254183B (zh) * 2013-05-10 2015-11-11 苏州明锐医药科技有限公司 阿法替尼的制备方法
CN103254182A (zh) * 2013-05-10 2013-08-21 苏州明锐医药科技有限公司 一种阿法替尼的制备方法
WO2014180271A1 (zh) * 2013-05-10 2014-11-13 苏州明锐医药科技有限公司 阿法替尼及其中间体的制备方法
CN103242303B (zh) * 2013-05-16 2015-03-25 苏州明锐医药科技有限公司 阿法替尼的制备方法
WO2014183560A1 (zh) * 2013-05-16 2014-11-20 苏州明锐医药科技有限公司 阿法替尼及其中间体的制备方法
CN104513229A (zh) * 2013-09-28 2015-04-15 正大天晴药业集团股份有限公司 喹唑啉衍生物及其制备方法
CN103755688B (zh) * 2013-12-24 2015-11-18 江苏奥赛康药业股份有限公司 一种阿法替尼化合物的制备方法
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
EP3089976B1 (en) 2014-01-02 2019-08-14 Teva Pharmaceuticals International GmbH Crystalline forms of afatinib dimaleate
CN105315263B (zh) * 2014-07-30 2018-11-27 正大天晴药业集团股份有限公司 阿法替尼中间体的合成方法
EP3023421A1 (en) 2014-11-21 2016-05-25 Sandoz Ag Crystalline forms of afatinib dimaleate
CN105801568B (zh) 2015-01-15 2019-07-30 杭州普晒医药科技有限公司 阿法替尼一马来酸盐晶型及其制备方法和药物组合物
CN107406430B (zh) 2015-03-20 2019-04-26 正大天晴药业集团股份有限公司 喹唑啉衍生物的盐及其制备方法
CN105175400B (zh) * 2015-09-29 2018-04-10 河北神威药业有限公司 一种阿法替尼中间体的制备方法
WO2017141271A1 (en) * 2016-02-17 2017-08-24 Sun Pharmaceutical Industries Ltd. Stable pharmaceutical composition of afatinib
CN106442793B (zh) * 2016-10-21 2019-05-24 河北神威药业有限公司 一种制备阿法替尼的中间体及其对映异构体的检测方法
KR20230162125A (ko) 2016-11-10 2023-11-28 베링거 인겔하임 인터내셔날 게엠베하 약제학적 조성물, 치료 방법 및 이의 용도
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
EP3727387A4 (en) * 2017-12-18 2021-12-15 Sterngreene, Inc. PYRIMIDINE COMPOUNDS USEFUL AS TYROSINE KINASE INHIBITORS
CN110437163A (zh) * 2018-05-03 2019-11-12 斯特恩格林公司 作为酪氨酸激酶抑制剂的嘧啶类化合物
AU2019346550A1 (en) 2018-09-25 2021-04-22 Black Diamond Therapeutics, Inc. Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use
CN109265449B (zh) * 2018-11-07 2021-11-23 沈阳工业大学 Egfr和her2双靶点酪氨酸激酶抑制剂及制备方法和用途
KR20210107069A (ko) 2018-12-21 2021-08-31 다이이찌 산쿄 가부시키가이샤 항체-약물 컨쥬게이트와 키나아제 저해제의 조합
CN109824657A (zh) * 2019-03-26 2019-05-31 石药集团中奇制药技术（石家庄）有限公司 一种二马来酸阿法替尼新晶型及其制备方法和应用
CN110590682A (zh) * 2019-10-14 2019-12-20 重庆医科大学 一种制备阿法替尼杂质的方法以及制备的杂质
WO2021094379A1 (en) 2019-11-12 2021-05-20 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
KR20220130190A (ko) 2020-01-20 2022-09-26 아스트라제네카 아베 암 치료를 위한 표피성장인자 수용체 티로신 키나제 억제제
US20210369709A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
TWI847289B (zh) * 2021-09-30 2024-07-01 大陸商北京賽特明強醫藥科技有限公司 喹唑啉類化合物、組合物及其應用
JP2025510910A (ja) 2022-03-31 2025-04-15 アストラゼネカ・アクチエボラーグ 癌の処置のための、ａｋｔ阻害剤との組み合わせにおける上皮成長因子受容体（ｅｇｆｒ）チロシンキナーゼ阻害剤
WO2023209090A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their application in the treatment of cancer
WO2023209086A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds for treating cancer
AU2023262556A1 (en) 2022-04-28 2024-12-05 Astrazeneca Ab Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209088A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their use in the treatment of cancer
MA71241A (fr) 2022-06-27 2025-04-30 Astrazeneca Ab Combinaisons impliquant des inhibiteurs de tyrosine kinase du récepteur du facteur de croissance épidermique pour traiter le cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA001595B1 (ru) * 1996-04-12 2001-06-25 Варнер-Ламберт Компани Необратимые ингибиторы тирозинкиназ
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ZA986729B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
DE19908567A1 (de) * 1999-02-27 2000-08-31 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
IL144143A0 (en) * 1999-02-27 2002-05-23 Boehringer Ingelheim Pharma 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases
DE19911366A1 (de) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE19911509A1 (de) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DK1731511T3 (en) * 1999-06-21 2015-10-26 Boehringer Ingelheim Pharma Bicyclic heterocyclic structures, pharmaceutical compositions containing these compounds, their use and process for their preparation
CA2403152C (en) * 2000-04-08 2008-10-28 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them

Also Published As

Publication number Publication date
NO2014003I2 (no) 2015-10-19
NO20032726D0 (no) 2003-06-16
TWI295992B (en) 2008-04-21
EA006317B1 (ru) 2005-10-27
CY1109290T1 (el) 2014-07-02
CN1481370A (zh) 2004-03-10
IL156277A0 (en) 2004-01-04
PT1345910E (pt) 2009-07-14
HK1060571A1 (en) 2004-08-13
DE50114874D1 (de) 2009-06-10
ZA200304141B (en) 2004-04-15
MEP59508A (en) 2011-05-10
EP1345910A1 (de) 2003-09-24
LU92370I2 (fr) 2014-03-31
LTPA2014005I1 (lt) 2022-05-25
FR14C0009I1 (fr) 2014-03-07
AR040524A1 (es) 2005-04-13
BG66139B1 (bg) 2011-07-29
SK287573B6 (sk) 2011-03-04
PL361798A1 (en) 2004-10-04
CN1277822C (zh) 2006-10-04
AU1917402A (en) 2002-07-01
NO2014003I1 (no) 2014-06-02
YU49603A (sh) 2006-05-25
CZ302721B6 (cs) 2011-09-21
WO2002050043A1 (de) 2002-06-27
EA200300671A1 (ru) 2004-06-24
CY2014008I2 (el) 2015-12-09
MXPA03005559A (es) 2004-10-14
EP1345910B1 (de) 2009-04-29
HUP0301852A3 (en) 2008-03-28
ES2326617T3 (es) 2009-10-16
EP1345910B9 (de) 2014-06-04
CZ20031930A3 (cs) 2003-10-15
LTC1345910I2 (lt) 2022-06-10
JP3827641B2 (ja) 2006-09-27
UA74614C2 (en) 2006-01-16
HRP20030504A2 (en) 2005-06-30
BG107929A (bg) 2005-01-31
NO325672B1 (no) 2008-07-07
BRPI0116266B1 (pt) 2017-10-31
CA2432428A1 (en) 2002-06-27
HUS1400005I1 (hu) 2017-08-28
UY27078A1 (es) 2002-07-31
ES2326617T9 (es) 2014-09-10
EP2112140A1 (de) 2009-10-28
MY136086A (en) 2008-08-29
DK1345910T3 (da) 2009-07-20
ME02777B (me) 2011-10-10
BE2014C009I2 (en, 2012) 2021-02-04
NO2022028I1 (no) 2022-07-01
IL156277A (en) 2009-12-24
LU92370I9 (en, 2012) 2019-01-17
KR100852102B1 (ko) 2008-08-13
EE200300300A (et) 2003-10-15
CY2014008I1 (el) 2014-07-02
HU228874B1 (en) 2013-06-28
CA2432428C (en) 2009-09-01
FR14C0009I2 (fr) 2014-11-14
NZ526918A (en) 2006-11-30
PL214798B1 (pl) 2013-09-30
AU2002219174B2 (en) 2007-09-06
HRP20030504B1 (en) 2011-09-30
RS50860B (sr) 2010-08-31
DE10063435A1 (de) 2002-07-04
BR0116266A (pt) 2004-02-17
BRPI0116266B8 (pt) 2021-07-27
KR20030071787A (ko) 2003-09-06
ATE430136T1 (de) 2009-05-15
SI1345910T1 (sl) 2009-08-31
NO20032726L (no) 2003-06-16
JP2004516283A (ja) 2004-06-03
HUP0301852A2 (hu) 2003-09-29
SK7712003A3 (en) 2003-10-07

Similar Documents

Publication Publication Date Title
EE200300300A (et) Kinasoliinderivaadid, neid ühendeid sisaldavad ravimid, nende kasutamine ja meetod nende valmistamiseks
EE05269B1 (et) Bitsüklilised heterotsüklilised ühendid, neid ühendeid sisaldavad ravimid, nende kasutamine ja meetodid nende valmistamiseks
EE9800277A (et) 4-aminopürimidiinderivaadid, neid ühendeid sisaldavad ravimid, nende kasutamine ja meetod nende valmistamiseks
EE04748B1 (et) Bitsüklilised heterotsüklilised ühendid, neid ühendeid sisaldavad ravimid, nende kasutamine ja meetodid nende valmistamiseks
EE200100431A (et) 16-halogenoepotilooni derivaadid, nende valmistamismeetod ja farmatseutiline kasutamine
NO20032733L (no) Difenylazetidinonderivater, fremgangsmåte for deres fremstilling, legemidler som inneholder disse forbindelsene og deres anvendelse
EE05240B1 (et) Orto- ja meta-asendatud bisarlhendid, nende kasutamine ja neid sisaldavad farmatseutilised preparaadid
NO20024175D0 (no) Azetidinderivater, deres fremstilling og farmasöytiske forbindelser inneholdende de samme
NO20032735L (no) Difenylazetidinonderivater, fremgangsmåte for deres fremstilling, legemidler som inneholder disse forbindelsene samt deres anvendelse
EE05134B1 (et) Adamantaani derivaadid, meetod nende valmistamiseks, neid sisaldavad ravimkoostised ja nende kasutamine ravis
EE200200369A (et) Asendatud piperidiinid, neid ühendeid sisaldavad ravimid ja meetodid nende valmistamiseks
EE200200095A (et) Sulfonüülkarboksamiidi derivaadid, nende kasutamine, ravim ja nende valmistamismeetod
EE05183B1 (et) Asabitsklilised hendid, nende valmistamine ja kasutamine ravimitena ning neid sisaldav farmatseutiline kompositsioon
NO20021719L (no) 6-posisjon substituerte indoliner, fremstilling og anvendelse derav som medikament
EE200300327A (et) Uurea derivaadid, nende valmistamismeetodid, kasutamine ja farmatseutiline kompositsioon
EE200200149A (et) Kinasoliinühendid ja neid sisaldavad ravimkoostised
NO20011216L (no) Azetidinderivater, deres fremstilling og medikamenter inneholdende forbindelsene
NO20025879D0 (no) Acylfenylureaderivater, fremgangsmåte for fremstilling derav og deres anvendelse som et legemiddel
EE04779B1 (et) 1,3-dihüdro-2H-indool-2-ooni derivaadid, nende valmistamismeetod ja neid sisaldavad farmatseutilised kompositsioonid
AU2001284021A1 (en) Quinazoline derivatives, medicaments containing these compounds, their use, and methods for the production thereof
EE04464B1 (et) Indalüülasendatud benseenkarboksamiidid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
EE200300254A (et) Heterotsüklilised ühendid, millel on antibakteriaalne toime, nende valmistamismeetod ja neid sisaldavad farmatseutilised kompositsioonid
EE04721B1 (et) Fenüülksantiini derivaadid, nende valmistamismeetodid ja kasutamine
EE200200041A (et) Karboksüülhappeamiidid, neid ühendeid sisaldavad ravimid, nende kasutamine ja valmistamine
ATA59499A (de) Pharmazeutische, tolperison enthaltende zubereitung zur oralen verabreichung

Legal Events

Date Code Title Description
HB1A Correction of owner name or address
KB4A Valid patent at the end of a year

Effective date: 20101231

AA1Y Spc filed

Free format text: PRODUCT NAME: AFATINIIB;REG NO/DATE: K(2013)6342 (LOPLIK) 25.09.2013

Spc suppl protection certif: C20140003

Filing date: 20140213

FG1Y Spc granted

Free format text: PRODUCT NAME: AFATINIIB;REG NO/DATE: K(2013)6342 (LOPLIK) 25.09.2013

Spc suppl protection certif: C20140003 00098

Filing date: 20140213

Extension date: 20261212

SPCT Party data change related to a supplementary protection certificate

Spc suppl protection certif: 00098

SPCZ Extension of supplementary protection certificate: granted [paediatric extension]

Free format text: PRODUCT: AFATINIIB

Spc suppl protection certif: C20140003

Extension date: 20270612